C
루닛
328130KOSDAQ45.5 / 100
Reference Date: 2026-10-23
Financial Score15.0 / 40
News Sentiment12.5 / 25
Momentum8.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Surged 33.8% over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
Lunit is a deep learning-based medical AI company specializing in cancer diagnosis and breast cancer screening solutions, leveraging AI-assisted detection and imaging biomarker technologies. Its core products, Lunit INSIGHT and Lunit SCOPE, drive innovation in the medical AI market, with 92% of revenue generated from overseas markets, including the U.S. and Japan.
Number of Employees
272people
Average Salary
93.2M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 15.004.0Point
PBR
5.98Industry Average 1.200.0Point
5.0x industry avg (risky)
ROE
-31.58Industry Average 8.000.0Point
Well below industry avg
Debt Ratio
14.75Industry Average 100.008.0Point
Half of industry avg (excellent)
Trend 2023~20253.0 / 10 points
Revenue Growth Rate
3.0 / 3
Avg ▲84.7% (2-year basis)
Operating Profit Growth Rate
0.0 / 3
Avg ▼41.5% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -32.3% (declining, 3yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position1.0Point
Near 52w low (7%, downtrend)
Current 11,040Won52-week high 45,92852-week low 8,250
1-month return6.0Point
1m +33.82% (strong rise)
Volume trend1.0Point
Volume decreasing
Detailed Disclosure
3 totalPositive 0Neutral 3Negative 0
- Neutral전환사채(해외전환사채포함)발행후만기전사채취득2026-10-02
- Neutral전환가액의조정2026-10-01
- Neutral전환사채(해외전환사채포함)발행후만기전사채취득2026-09-28